|
|
|
|
| LEADER |
05018nma a2201321 u 4500 |
| 001 |
EB001985355 |
| 003 |
EBX01000000000000001148257 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a 9783039282142
|
| 020 |
|
|
|a books978-3-03928-215-9
|
| 020 |
|
|
|a 9783039282159
|
| 100 |
1 |
|
|a Dullaart, Robin P.F.
|
| 245 |
0 |
0 |
|a Novel Aspects of Lipoprotein Metabolism with Focus on Systemic Inflammation
|h Elektronische Ressource
|
| 260 |
|
|
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
| 300 |
|
|
|a 1 electronic resource (248 p.)
|
| 653 |
|
|
|a passive diffusion
|
| 653 |
|
|
|a Type 2 diabetes mellitus
|
| 653 |
|
|
|a insulin resistance
|
| 653 |
|
|
|a CANTOS
|
| 653 |
|
|
|a ANGPTL8
|
| 653 |
|
|
|a lipoprotein metabolism
|
| 653 |
|
|
|a sodium intake
|
| 653 |
|
|
|a gut microbiota
|
| 653 |
|
|
|a free thiols
|
| 653 |
|
|
|a platelets
|
| 653 |
|
|
|a HDL function
|
| 653 |
|
|
|a trimethylamine N-oxide related metabolites
|
| 653 |
|
|
|a type 2 diabetes mellitus
|
| 653 |
|
|
|a LDL
|
| 653 |
|
|
|a renal transplant recipient
|
| 653 |
|
|
|a miR-33a
|
| 653 |
|
|
|a GlycA
|
| 653 |
|
|
|a chronic kidney disease
|
| 653 |
|
|
|a prognosis
|
| 653 |
|
|
|a cardiovascular disease
|
| 653 |
|
|
|a biomarker
|
| 653 |
|
|
|a triglycerides
|
| 653 |
|
|
|a fatty liver index
|
| 653 |
|
|
|a anti-apoA-1 IgG
|
| 653 |
|
|
|a ANGPTL4
|
| 653 |
|
|
|a LDL cholesterol
|
| 653 |
|
|
|a canakinumab
|
| 653 |
|
|
|a visceral adipose tissue (VAT)
|
| 653 |
|
|
|a lipoproteins
|
| 653 |
|
|
|a carbamoylation
|
| 653 |
|
|
|a anti-apolipoprotein A-1 antibodies
|
| 653 |
|
|
|a metabolic syndrome
|
| 653 |
|
|
|a phospholipid transfer protein activity
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a microvesicles
|
| 653 |
|
|
|a betaine
|
| 653 |
|
|
|a anti-apolipoprotein A-1 IgG
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a acute coronary syndrome
|
| 653 |
|
|
|a cytokines
|
| 653 |
|
|
|a adipose tissue
|
| 653 |
|
|
|a paraoxonase-1
|
| 653 |
|
|
|a C-statistics
|
| 653 |
|
|
|a anti-apolipoprotein A-I autoantibodies
|
| 653 |
|
|
|a familial hypercholesterolemia
|
| 653 |
|
|
|a nuclear magnetic resonance spectroscopy
|
| 653 |
|
|
|a interleukin 1?
|
| 653 |
|
|
|a foam cells
|
| 653 |
|
|
|a autoantibodies
|
| 653 |
|
|
|a atherothrombosis
|
| 653 |
|
|
|a ANGPTL3
|
| 653 |
|
|
|a diabetic cardiomyopathy
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a C-reactive protein
|
| 653 |
|
|
|a lipoprotein subfractions
|
| 653 |
|
|
|a leukocytes
|
| 653 |
|
|
|a adiponectin
|
| 653 |
|
|
|a cholesterol-lowering therapies
|
| 653 |
|
|
|a myocardial infarction
|
| 653 |
|
|
|a cholesterol
|
| 653 |
|
|
|a obesity
|
| 653 |
|
|
|a large VLDL
|
| 653 |
|
|
|a HOMA-IR
|
| 653 |
|
|
|a hepatic steatosis index
|
| 653 |
|
|
|a microparticles
|
| 653 |
|
|
|a metabolic disorder
|
| 653 |
|
|
|a retinol
|
| 653 |
|
|
|a cholesterol efflux capacity
|
| 653 |
|
|
|a HDL
|
| 653 |
|
|
|a cardiovascular events
|
| 653 |
|
|
|a endothelial cells
|
| 653 |
|
|
|a GRACE score
|
| 653 |
|
|
|a lipid metabolism
|
| 653 |
|
|
|a coronary artery calcium score
|
| 653 |
|
|
|a small LDL
|
| 653 |
|
|
|a Breast cancer
|
| 653 |
|
|
|a TLR2/4
|
| 653 |
|
|
|a large very low density lipoproteins
|
| 653 |
|
|
|a cholesterol homeostasis
|
| 653 |
|
|
|a atherosclerotic cardiovascular disease (ASCVD)
|
| 653 |
|
|
|a infrared spectroscopy
|
| 653 |
|
|
|a retinol binding protein 4
|
| 653 |
|
|
|a non-alcoholic fatty liver
|
| 653 |
|
|
|a lipids
|
| 653 |
|
|
|a 27-hydroxycholesterol
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by-nc-nd/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-03928-215-9
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/2079
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/54865
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 333
|
| 082 |
0 |
|
|a 580
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a With cardiometabolic diseases still topping the list of mortality causes and in facing the obesity and diabetes epidemic, there remains a great need to better understand the pathophysiological derangements underlying these conditions. During the past years, it has become increasingly appreciated that low grade systemic inflammation is a common hallmark of cardiometabolic disorders-not only concerning diabetes and atherosclerotic cardiovascular disease but also involving non-alcoholic fatty liver disease. Recently developed high-throughput laboratory techniques for lipidomics and metabolomics have enabled researchers to discern novel crosstalk pathways between lipid phenotypes and enhanced chronic inflammation. With this Special Issue of the Journal of Clinical Medicine, entitled "Novel Aspects of Lipoprotein Metabolism with a Focus on Systemic Inflammation", researchers were invited to submit original papers and reviews on various topics, in particular, at the interface of lipid metabolism and inflammation.
|